About: The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
Creator	Bakhshaliyev, Nijad Enhos, Asim Karacop, Erdem Ozdemir, Ramazan Uluganyan, Mahmut
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: The combination of Hydroxychloroquine (HCQ) and azithromycin showed effectiveness as a treatment for COVID-19 and is being used widely all around the world. Despite that those drugs are known to cause prolonged QT interval individually there is no study assessing the impact of this combination on electrocardiography (ECG). This study aimed to assess the impact of a 5-day course of HCQ and azithromycin combination on ECG in non-ICU COVID19(+) patients. METHODS: In this retrospective observational study, we enrolled 109 COVID19(+) patients who required non-ICU hospitalization. All patients received 5-day protocol of HCQ and azithromycin combination. On-treatment ECGs were repeated 3-6 h after the second HCQ loading dose and 48-72 h after the first dose of the combination. ECGs were assessed in terms of rhythm, PR interval, QRS duration, QT and QTc intervals. Baseline and on-treatment ECG findings were compared. Demographic characteristics, laboratory results were recorded. Daily phone call-visit or bed-side visit were performed by attending physician. RESULTS: Of the 109 patients included in the study, the mean age was 57.3 ± 14.4 years and 48 (44%) were male. Mean baseline PR interval was 158.47 ± 25.10 ms, QRS duration was 94.00 ± 20.55 ms, QTc interval was 435.28 ± 32.78 ms, 415.67 ± 28.51, 412.07 ± 25.65 according to Bazett's, Fridericia's and Framingham Heart Study formulas respectively. ∆PR was −2.94 ± 19.93 ms (p = .55), ∆QRS duration was 5.18 ± 8.94 ms (p = .03). ∆QTc interval was 6.64 ± 9.60 ms (p = .5), 10.67 ± 9.9 ms (p = .19), 14.14 ± 9.68 ms (p = .16) according to Bazett's, Fridericia's and Framingham Heart Study formulas respectively. There were no statistically significant differences between QTc intervals. No ventricular tachycardia, ventricular fibrillation or significant conduction delay was seen during follow-up. There was no death or worsening heart function. CONCLUSION: The 5-day course of HCQ- AZM combination did not lead to clinically significant QT prolongation and other conduction delays compared to baseline ECG in non-ICU COVID19(+) patients.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1016/j.jelectrocard.2020.08.008
bibo:pmid	32827987
has license	no-cc
sha1sum (hex)	2c3d85c2a0d08d8e40917e911118de40998caff6
schema:url	https://doi.org/10.1016/j.jelectrocard.2020.08.008
resource representing a document's title	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
has PubMed Central identifier	PMC7417268
has PubMed identifier	32827987
schema:publication	J Electrocardiol
resource representing a document's body	covid:2c3d85c2a0d08d8e40917e911118de40998caff6#body_text
is schema:about of	named entity 'azithromycin' named entity 'Journal' named entity 'combination' named entity 'CITE' named entity 'PATIENTS' named entity 'https' named entity 'COVID19' named entity 'hydroxychloroquine' named entity 'coronavirus disease 2019' named entity 'QT interval' named entity 'COVID19' named entity 'Azithromycin' named entity 'cardiovascular' named entity 'mmol/L' named entity 'azithromycin' named entity 'lower respiratory infection' named entity 'ECGs' named entity 'attending physician' named entity 'comorbidity' named entity 'Oral bioavailability' named entity 'loading dose' named entity 'action potential' named entity 'potassium' named entity 'QT interval' named entity 'cohort study' named entity 'QT interval' named entity 'pathologies' named entity 'oseltamivir' named entity 'clinical practice' named entity 'Azithromycin' named entity 'ECG' named entity 'HCQ' named entity 'QT interval' named entity 'macrolide' named entity 'ECG' named entity 'antiviral medication' named entity 'viral load' named entity 'sample size' named entity 'Azithromycin' named entity 'penicillin' named entity 'Hydroxychloroquine' named entity 'sinus' named entity 'D-dimer' named entity 'December 9' named entity 'electrolytes' named entity 'azithromycin' named entity 'hypoxia' named entity 'Journal of Electrocardiology' named entity 'HCQ' named entity 'HCQ' named entity 'cytochrome enzymes' named entity 'China' named entity 'COVID19' named entity 'serum' named entity 'SARS-CoV-2 outbreak' named entity 'QT prolongation' named entity 'Pregnancy' named entity 'intensive care unit' named entity 'Azithromycin' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'single center' named entity 'ICU' named entity 'proarrhythmic' named entity 'intubated' named entity 'azithromycin' named entity 'asymptomatic' named entity 'ECG' named entity 'potassium' named entity 'QT prolongation' named entity 'azithromycin' named entity 'in-patient' named entity 'bundle branch block' named entity 'potassium' named entity 'Hydroxychloroquine' named entity 'potassium ion channels' named entity 'Hydroxychloroquine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software